Where once pharmacovigilance was regarded as a necessary burden, pharmaceutical companies are starting to recognise that safety in fact plays an integral role in business strategy, such as in decisions regarding mergers and acquisitions (M&A). Marco Anelli, MD, head of pharmacovigilance and medical affairs advisory services at ProductLife Group explores how the changing environment is affecting what is required of pharmacovigilance leaders, as well as how safety data is gathered, managed, and turned into critical reports and documents.
https://www.jforcs.com/7/wp-content/uploads/2016/07/Demand-for-Data.pdf